Former Orthofix vice president of sales Thomas Guerrieri pleads guilty to federal charges that he helped run a scheme to pay doctors to use Orthofix's bone-growth stimulators; also, Guidant whistleblower asks court to re-open off-label stent case; and 200 Irish plaintiffs join DePuy lawsuit spree. A former vice president of sales for Orthofix (NSDQ:OFIX) faces up to 5 years in prison after pleading guilty to federal charges that he helped run a scheme to pay doctors to use the company's Spinal-Stim and Cervical-Stim bone growth stimulators.